SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    0.00 (0.00%)
Bid:
1.10
Ask:
1.30
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

FundamentalVR Fund Raise

31 May 2022 07:00

RNS Number : 3134N
Tern PLC
31 May 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

31 May 2022

 

Tern Plc

("Tern" or the "Company")

 

FundamentalVR Fund Raise

 

Tern Plc (AIM:TERN), the company focused on value creation from Internet of Things ("IoT") technology businesses, is pleased to announce that FVRVS Limited ("FundamentalVR"), has undertaken a Series B fund raising round, securing £7 million in new equity investment (the "FundamentalVR Series B") from existing investors and a new institutional investor, at a valuation uplift of 77% from the previous book valuation of Tern's holding.

 

Highlights

 

· FundamentalVR has raised a total of £7 million in a Series B fund raising from existing investors and a new institutional investor, with an additional £1.2 million of convertible loan notes being converted

 

· Tern has converted approximately £570,000 in loan notes and accrued interest it held in FundamentalVR into equity, in line with the terms of these loan notes, but will invest no new money in the FundamentalVR Series B

 

· The FundamentalVR Series B is intended to provide FundamentalVR with funding to enable to grow in line with its strategy, including expanding its US activities

 

· With the completion of the £7 million FundamentalVR Series B, including the conversion of Tern's loan notes to equity, Tern will hold 20.0% of FundamentalVR's equity, valued at £6.3 million at the valuation implied by the FundamentalVR Series B price

 

FundamentalVR Fund Raise

 

Prior to the FundamentalVR Series B, Tern had a holding of 26.9% in FundamentalVR, plus a loan convertible into FundamentalVR equity of £530,000 and accrued interest of £39,932. As at 31 December 2021, the date of Tern's last published book valuation, this holding had an audited book value of £3.6 million. 

 

Following the FundamentalVR Series B funding of £7 million, the conversion of Tern's £0.53 million of loan notes and the conversion of £0.63 million of loan notes held by other investors, FundamentalVR is now valued in total at approximately £23 million on a pre-money basis and Tern now has a holding of 20.0% in FundamentalVR (before any dilution on exercise of any future FundamentalVR employee share options), with an unaudited book valuation of £6.3 million, representing a 77% uplift on the 31 December 2021 book value of Tern's holding.

 

Further information on FundamentalVR

 

FundamentalVR delivers virtual reality haptic 'flight simulators' for surgery creating a safe, measurable and repeatable space to refine skills. FundamentalVR's goal is to transform the way surgeons prepare, practice, and refine their skills. It has built an immersive, surgical simulation application platform, Fundamental Surgery, to provide medical professionals with the opportunity to rehearse, practice, and test themselves within a safe, controllable space that is as close to real-life as possible.

 

According to the latest filed financial statements for FundamentalVR, for the 12 month period ended 31 December 2020, the business recorded an increase in retained unaudited losses of £2.12 million and at that date had unaudited net assets of approximately £1.27 million. Given the historic nature of these figures Tern does not consider this to be representative of the current business and trading performance of FundamentalVR.

 

Further information on FundamentalVR may be found at: https://www.fundamentalvr.com

 

Enquiries

 

Tern Plc

Al Sisto (CEO)

Sarah Payne (CFO)

via IFC Advisory

 

Allenby Capital Limited

(Nominated Adviser and Broker)

David Worlidge / Alex Brearley (Corporate Finance)

Matt Butlin / Kelly Gardiner (Sales and Corporate Broking)

 

Tel: 0203 328 5656

 

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Chandler

 

Tel: 0203 934 6630

tern@investor-focus.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKKBDKBKBCPN
Date   Source Headline
8th Jun 20267:00 amRNSNotice of AGM
29th May 20265:00 pmRNSTotal Voting Rights
26th May 20267:00 amRNSInvestment in Talking Medicines CLNs
22nd May 20267:00 amRNSDevice Authority Convertible Loan Notes Investment
19th May 20267:00 amRNSPlacing to raise £222,000
12th May 20267:00 amRNS-RDevice Authority Strategic Partnership
8th May 202612:53 pmRNSResult of GM & Update on Open Offer
8th May 20267:00 amRNSResults of Open Offer
21st Apr 20267:00 amRNSOpen Offer and Notice of General Meeting
31st Mar 20265:00 pmRNSTotal Voting Rights
5th Mar 20267:00 amRNSExtension of loan facility agreement
3rd Mar 20267:00 amRNSResults of Open Offer
13th Feb 20267:00 amRNSOpen Offer at 0.40p to raise up to £384,408
5th Feb 20267:00 amRNS-RTern Notes Automotive Momentum at Device Authority
15th Jan 20267:00 amRNSUpdate regarding SVV2
8th Jan 20267:00 amRNSInvestor Presentations
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
23rd Dec 20257:00 amRNS-ROnline Investor Presentation and Q&A Session
12th Dec 20257:00 amRNSIssue of Talking Medicines Convertible Loan Notes
28th Nov 20257:00 amRNSUpdate regarding capital commitment to SVV2
25th Nov 20257:00 amRNSTalking Medicines CLN Modifications
31st Oct 20253:35 pmRNSTotal Voting Rights
15th Oct 20257:00 amRNSResults of Open Offer
9th Oct 20257:00 amRNSRemuneration Reductions & Distribution Commitment
29th Sep 20257:00 amRNSOpen Offer to raise up to £642,486
15th Sep 20257:00 amRNSExtension of Loan Facility Term
4th Sep 20257:00 amRNSInterim results for the six months to 30 June 2025
1st Sep 20257:00 amRNSAppointment of shareholder relations adviser
31st Jul 20254:34 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSResults of underwritten Open Offer & TVR
24th Jul 20257:00 amRNSReceipt of Bridging Loan
14th Jul 20257:00 amRNSUnderwritten Open Offer to raise £642,486
30th Jun 202512:07 pmRNSResult of AGM
13th Jun 20257:00 amRNSDirector Share Purchase
11th Jun 20257:00 amRNSDirector Share Purchase
6th Jun 20257:00 amRNSNotice of AGM and Director Retirement
5th Jun 20257:00 amRNSResults for the year ended 31 December 2024
30th May 20255:39 pmRNSTotal Voting Rights
7th May 20257:00 amRNSResults of Underwritten Open Offer
24th Apr 20257:00 amRNSPurple Transform appointment
17th Apr 20257:00 amRNSUnderwritten Open Offer to raise £340,140
11th Mar 20257:00 amRNS-RDevice Authority Microsoft & CyberArk Partnership
11th Mar 20257:00 amRNS-RSure Ventures Update
28th Feb 20255:00 pmRNSTotal Voting Rights
21st Feb 20257:00 amRNSPlacing to raise £221,154
14th Jan 20257:30 amRNS-RProgressive Equity Research Report
10th Jan 20257:00 amRNSInvestor Presentations
2nd Jan 20257:00 amRNSInvestment in Sure Ventures plc
31st Dec 20241:30 pmRNSTotal Voting Rights
23rd Dec 202411:39 amRNSDevice Authority update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.